AEON Biopharma (AEON) News Today $0.15 -0.02 (-9.89%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period AEON Biopharma (NASDAQ:AEON) Trading Down 9.9% - Should You Sell?January 15, 2025 | americanbankingnews.comAEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public OfferingJanuary 7, 2025 | globenewswire.comAEON Biopharma (AMEX:AEON) Stock Quotes, Forecast and News SummaryJanuary 6, 2025 | benzinga.comAeon Biopharma prices 40M units at 50c in underwritten public offeringJanuary 6, 2025 | markets.businessinsider.comAEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public OfferingJanuary 6, 2025 | markets.businessinsider.comAEON Biopharma announces share offeringJanuary 6, 2025 | msn.comAEON Biopharma, Inc. Announces Launch of Proposed Public OfferingJanuary 3, 2025 | globenewswire.comAEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | globenewswire.comKailera Therapeutics Appoints Scott M. Akamine as Chief Legal OfficerNovember 13, 2024 | finance.yahoo.comAEON Biopharma maps FDA path for Botox biosimilarOctober 2, 2024 | investing.comBuy Rating on AEON Biopharma: Strategic FDA Alignment and Positive Long-Term Revenue ProjectionsOctober 2, 2024 | markets.businessinsider.comAEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory MeetingOctober 1, 2024 | markets.businessinsider.comAEON Biopharma, Inc. (AEON) Stock Price, News, Quote & History - Yahoo FinanceAugust 22, 2024 | finance.yahoo.comAEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024August 19, 2024 | globenewswire.comAEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 12, 2024 | globenewswire.comAEON Biopharma (NASDAQ:AEON) Trading Down 11.8%AEON Biopharma (NASDAQ:AEON) Trading Down 11.8%August 1, 2024 | marketbeat.comAEON Biopharma (NASDAQ:AEON) Rating Reiterated by HC WainwrightHC Wainwright restated a "buy" rating and issued a $6.00 price target on shares of AEON Biopharma in a research report on Thursday.May 30, 2024 | marketbeat.comAEON Biopharma Cuts 55% Of Workforce, Terminates CFO To Preserve Cash; Stock Up In Pre-marketMay 29, 2024 | markets.businessinsider.comAEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction PlanMay 29, 2024 | globenewswire.comAEON Biopharma, Inc. (NASDAQ:AEON) Expected to Earn FY2028 Earnings of $0.18 Per ShareAEON Biopharma, Inc. (NASDAQ:AEON - Free Report) - Investment analysts at HC Wainwright issued their FY2028 EPS estimates for AEON Biopharma in a report issued on Wednesday, May 15th. HC Wainwright analyst D. Tsao anticipates that the company will earn $0.18 per share for the year. HC WainwrightMay 17, 2024 | marketbeat.comAEON Biopharma (NASDAQ:AEON) Price Target Cut to $6.00HC Wainwright dropped their target price on AEON Biopharma from $18.00 to $6.00 and set a "buy" rating on the stock in a research report on Wednesday.May 15, 2024 | marketbeat.comAEON Biopharma, Inc. (AEON)May 15, 2024 | finance.yahoo.comAEON Biopharma Reports First Quarter 2024 Financial ResultsMay 14, 2024 | globenewswire.comAEON Biopharma Provides Update on Development PipelineMay 9, 2024 | globenewswire.comMaintaining Buy on AEON Biopharma: Potential of ABP-450 Despite Phase 2 SetbackMay 7, 2024 | markets.businessinsider.comAEON Biopharma's (AEON) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of AEON Biopharma in a report on Monday.May 6, 2024 | marketbeat.comNewly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday - Read Here WhyMay 3, 2024 | msn.comUS Equity Markets Close Higher Friday Following Weak Jobs ReportMay 3, 2024 | finance.yahoo.comAEON Says Preliminary Results From Phase 2 Interim Analysis Of ABP-450 Fails To Meet Primary GoalMay 3, 2024 | markets.businessinsider.comAEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic MigraineMay 3, 2024 | globenewswire.comHC Wainwright Analysts Boost Earnings Estimates for AEON Biopharma, Inc. (NASDAQ:AEON)AEON Biopharma, Inc. (NASDAQ:AEON - Free Report) - Stock analysts at HC Wainwright upped their Q1 2024 earnings per share (EPS) estimates for AEON Biopharma in a report issued on Wednesday, April 17th. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.31) per share for theApril 19, 2024 | marketbeat.comAEON Biopharma: Buoyant Prospects Following FDA Alignment on Migraine StudiesApril 18, 2024 | markets.businessinsider.comAEON Biopharma, Inc. Forecasted to Earn Q1 2025 Earnings of ($0.29) Per Share (NASDAQ:AEON)AEON Biopharma, Inc. (NASDAQ:AEON - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for AEON Biopharma in a report released on Wednesday, April 17th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($0.29) for theApril 18, 2024 | marketbeat.comAEON Biopharma (NASDAQ:AEON) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of AEON Biopharma in a research report on Wednesday.April 17, 2024 | marketbeat.comCORRECTION -- AEON Biopharma Announces Redemption of Public WarrantsMarch 30, 2024 | globenewswire.comAEON Biopharma Announces Redemption of Public WarrantsMarch 29, 2024 | globenewswire.comAEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 29, 2024 | globenewswire.comLenz stock rallies 22% amid bullish note by Piper SandlerMarch 28, 2024 | seekingalpha.comAEON Biopharma secures $15 million in private placementMarch 21, 2024 | investing.comAEON Biopharma (NASDAQ:AEON) Shares Gap Down to $14.40AEON Biopharma (NASDAQ:AEON) Shares Gap Down to $14.40March 20, 2024 | marketbeat.comAEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of MigraineMarch 19, 2024 | globenewswire.comAEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase AgreementsMarch 19, 2024 | globenewswire.comAEON Biopharma (NASDAQ:AEON) Shares Down 7.2% AEON Biopharma (NASDAQ:AEON) Shares Down 7.2%March 19, 2024 | marketbeat.comAEON Biopharma (NASDAQ:AEON) Reaches New 12-Month High at $15.98AEON Biopharma (NASDAQ:AEON) Sets New 52-Week High at $15.98March 18, 2024 | marketbeat.comAEON Biopharma (NASDAQ:AEON) Sees Strong Trading VolumeAEON Biopharma (NASDAQ:AEON) Sees Unusually-High Trading VolumeMarch 15, 2024 | marketbeat.comAEON Biopharma, Inc. Class AFebruary 26, 2024 | edition.cnn.comDaewoong Pharmaceutical Co., Ltd.: Daewoong Pharmaceutical Announces 2023 Financial ResultsFebruary 6, 2024 | finanznachrichten.deAeon Kyushu Co Ltd 2653February 1, 2024 | morningstar.comAEON.WS AEON Biopharma, Inc. WT EXP 072128January 31, 2024 | seekingalpha.comAEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin ConferenceJanuary 18, 2024 | finance.yahoo.com Get AEON Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter. Email Address AEON Media Mentions By Week AEON Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AEON News Sentiment▼-0.180.44▲Average Medical News Sentiment AEON News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AEON Articles This Week▼10▲AEON Articles Average Week Get AEON Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PULM News NXTC News CARA News TRAW News TENX News XCUR News COCP News ATHA News GOVX News MIRA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AEON) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.